Bicycle Therapeutics PLC (BCYC)
23.09
-0.21
(-0.90%)
USD |
NASDAQ |
May 07, 16:00
23.08
-0.01
(-0.03%)
After-Hours: 20:00
Bicycle Therapeutics Cash from Financing (TTM): 249.18M for March 31, 2024
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
March 31, 2024 | 249.18M |
December 31, 2023 | 250.03M |
September 30, 2023 | 255.53M |
June 30, 2023 | 21.06M |
March 31, 2023 | 8.96M |
December 31, 2022 | 6.692M |
September 30, 2022 | 191.47M |
June 30, 2022 | 231.76M |
March 31, 2022 | 247.12M |
December 31, 2021 | 320.72M |
September 30, 2021 | 131.80M |
Date | Value |
---|---|
June 30, 2021 | 152.44M |
March 31, 2021 | 136.90M |
December 31, 2020 | 62.84M |
September 30, 2020 | 61.22M |
June 30, 2020 | -0.677M |
March 31, 2020 | 58.41M |
December 31, 2019 | 58.44M |
September 30, 2019 | 83.75M |
June 30, 2019 | 84.56M |
March 31, 2019 | 25.46M |
December 31, 2018 | 25.43M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-0.677M
Minimum
Jun 2020
320.72M
Maximum
Dec 2021
130.61M
Average
108.18M
Median
Cash from Financing (TTM) Benchmarks
Biodexa Pharmaceuticals Plc | 12.76M |
NuCana PLC | -0.0659M |
TC BioPharm (Holdings) PLC | 10.62M |
Adaptimmune Therapeutics PLC | 0.88M |
Autolus Therapeutics PLC | -0.883M |